CHINARES PHARMA leads the establishment of a 500 million fund, focusing on synthetic biology and innovative drug fields
CHINARES PHARMA announced that it has signed a limited partnership agreement with its subsidiaries and other partners to establish a fund with a scale of RMB 500 million, focusing on investments in synthetic biology and innovative pharmaceuticals. CHINARES PHARMA will contribute RMB 123 million, accounting for 24.6% of the total commitment of the fund. The fund aims to optimize the group's strategic layout in related fields and promote the construction of a synthetic biology industrialization platform. The fund will be managed by Shenzhen China Resources Capital and will be recorded as equity investment after its establishment
According to the Zhitong Finance APP, CHINARES PHARMA (03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), China Resources Double Crane (as the limited partner), and CHINARES PHARMA Investment (as the limited partner) (each being a subsidiary of the company) entered into a limited partnership agreement with other partners to establish a proposed fund with a scale of RMB 500 million. The fund will primarily invest in high-growth enterprises in the fields of synthetic biology, innovative drugs, and biotechnology. The group plans to commit a total investment of RMB 123 million, accounting for approximately 24.6% of the total committed capital of the fund. After its establishment, the fund will not be accounted for as a subsidiary of the company. Shenzhen China Resources Capital will be entrusted as the fund manager.
Synthetic biology is one of the strategic development directions of the group. By establishing the fund, the group aims to build a synthetic biology industrialization platform in Hohhot, optimizing the group's strategic layout in related key areas. In addition, leveraging the synergistic advantages of industrial development in Hohhot, the group expects the fund to achieve goals such as enriching investment channels in the synthetic biology industry, promoting innovation incubation, accelerating product technology cooperation, and obtaining commercial product rights. After the establishment of the fund, it will be accounted for as equity investment in the company's consolidated financial statements
